- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03028025
Comparing TR Band to Statseal in Conjunction With TR Band
March 29, 2021 updated by: Arnold Seto, VA Long Beach Healthcare System
Radial Hemostasis is Facilitated With a Potassium Ferrate Hemostatic Patch (Statseal): the Randomized Controlled Statseal With TR Band Assessment Trial (STAT)
The primary objectives of this study are to evaluate the performance of StatSeal Advanced used in conjunction with the TR Band (SSA) as compared to the TR Band without SSA (TRB) relative to: the incidence of peri-procedural radial artery occlusion (RAO) at discharge or 24 hours, whichever occurs first, and the Time to Hemostasis (TTH).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is a physician initiated, prospective, observational, two arm, randomized study to be performed at up to four experienced 'Radial First' centers (UCSD, UCLA.
Arkansas Heart Hospital and LBVA).
A maximum of 180 patients having undergone successful radial catheterization will be enrolled in the study, 60 in each arm.
60 patients will be enrolled at the LBVA.
Enrollment will continue at each site on discretion of the investigators until each center enrolls a minimum of 30 patients, or a maximum of 180 patients are enrolled.
Clinicians will perform the catheterization in accordance with local standard practice, with a minimum of 5,000 units of unfractionated heparin for anticoagulation.
At the start of the TRA procedure, prior to radial artery cannulation, a baseline Pleth-ox exam will be performed for all patients and recorded on the CRF.
Ulnar compression will be applied to confirm that the radial artery is patent.
Patients with a type D pattern exam will be excluded from the study.
At the conclusion of a successful transradial procedure, the patient will be randomized to either SSA or TRB, each device applied per protocol & IFU.
It is hypothesized that if radial artery compression time can be shortened to 40 minutes or less, the following could result: improved catheterization lab efficiency, greater patient satisfaction and lower complication rates, including RAO, may be improved.
Study Type
Interventional
Enrollment (Actual)
184
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Long Beach, California, United States, 90822
- Veteran Affairs Long Beach
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient undergoing diagnostic angiography or PCI via the radial artery
- Patients with a Barbeau test prior to the procedure showing pattern A,B,or
Exclusion Criteria:
- Use of a radial sheath larger than 6 Fr (a 7Fr-in-6 Glidesheath Slender ® is allowed).
- Use of an anticoagulant other than unfractionated heparin or bivalirudin.
- Any anticipated need for continued anticoagulation post-catheterization. Glycoprotein inhibitors are acceptable.
- Any active treatment with oral anticoagulants continued during course of procedure.
- Presence of arteriovenous dialysis fistula in the ipsilateral arm.
- Any physical deformity or trauma / injury of either wrist that would prevent proper placement or function of the hemostasis band.
- Raynaud's syndrome or known peripheral vascular disease of the forearm.
- Mental incompetence or inability to follow the instructions to complete the study.
- History or presence of Radial Artery Occlusion.
- Barbeau test showing Pattern D.
- Patients undergoing catheterization from the femoral or ulnar artery approach.
- Cardiogenic shock or any clinical instability as assessed by the physician performing the procedure.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: TR Band Only
TR Band: Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air.
After aspirating and clearing the contents of the sheath, the radial sheath will be removed.
The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis.
Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours.
The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
|
Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air.
After aspirating and clearing the contents of the sheath, the radial sheath will be removed.
The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis.
Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours.
The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
Other Names:
|
|
Experimental: Statseal with TR Band
StatSeal: Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm.
A Tegaderm dressing will be applied to secure the disc position.
The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc.
The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed.
No deflation will occur immediately.
After 20 minutes of pressure, 3 cc of air will be removed from the TR band.
After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place.
After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
|
Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm.
A Tegaderm dressing will be applied to secure the disc position.
The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc.
The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed.
No deflation will occur immediately.
After 20 minutes of pressure, 3 cc of air will be removed from the TR band.
After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place.
After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Hemostasis Using the Hemostasis Management System (HMS)
Time Frame: within 30 min of discharge or after 24 hours
|
Time to deflation for removal of the TR Band (or TR Band and Statseal) for each group was measured in minutes.
|
within 30 min of discharge or after 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of Patients With Radial Artery Occlusion(RAO)
Time Frame: within 30 min of discharge or after 24 hours
|
Radial artery occlusion was monitored for all participants using Barbeau's test and pulse oximetry.
|
within 30 min of discharge or after 24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Arnold H Seto, M.D., VA Long Beach Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2017
Primary Completion (Actual)
August 1, 2017
Study Completion (Actual)
August 1, 2017
Study Registration Dates
First Submitted
January 13, 2017
First Submitted That Met QC Criteria
January 20, 2017
First Posted (Estimate)
January 23, 2017
Study Record Updates
Last Update Posted (Actual)
April 21, 2021
Last Update Submitted That Met QC Criteria
March 29, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Myocardial Ischemia
- Heart Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Pain
- Neurologic Manifestations
- Hemorrhage
- Coronary Disease
- Chest Pain
- Coronary Artery Disease
- Cardiovascular Diseases
- Atherosclerosis
- Angina Pectoris
- Hematoma
- Coagulants
- Hemostatics
Other Study ID Numbers
- MIRB 1427
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Hull University Teaching Hospitals NHS TrustNot yet recruitingCardiovascular Surgery | Cardiovascular Diseases (CVD)United Kingdom
-
Weill Medical College of Cornell UniversityAmerican Heart AssociationRecruitingCardiovascular | Cardiovascular Health | Cardiovascular (CV) Risk | Cardiovascular Disease (CVD) Risk FactorsUnited States
-
Fu Jen Catholic UniversityRecruitingCardiovascular Disease | Cardiovascular SurgeryTaiwan
-
Medical College of WisconsinNational Center for Complementary and Integrative Health (NCCIH)CompletedCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
IRCCS Policlinico S. DonatoIRCCS San Raffaele; Fondazione Policlinico Universitario Agostino Gemelli IRCCS and other collaboratorsRecruitingCardiovascular Risk | Genetic Cardiovascular RiskItaly
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
Children's Hospital Medical Center, CincinnatiRecruitingCardiovascular Diseases (CVD)United States
Clinical Trials on TR Band
-
Medical University of South CarolinaCompleted
-
University Medical Center GroningenCompletedCardiac CatheterisationNetherlands
-
Terumo Medical CorporationMedical University of South CarolinaCompleted
-
Sultan Qaboos UniversityCompletedCoronary Artery Disease | Radial Artery InjuryOman
-
VA Long Beach Healthcare SystemTerminatedCardiovascular Diseases | Coronary Artery Disease | Atherosclerosis | Arterial Occlusion | Hematoma | Anticoagulant-induced BleedingUnited States
-
Universitätsmedizin MannheimCompletedPercutaneous Coronary Intervention (PCI) | Arterial Closure Device | Access Site Bleeding | Adverse Cardiac EventsGermany
-
Aga Khan UniversityCompleted
-
Acibadem UniversityUnknownHematoma | Radial Artery Injury | BleedTurkey
-
Oslo University HospitalHelse Sor-OstCompletedHemostasis | Injury of Radial Artery | Peripheral Artery OcclusionNorway
-
Regional Hospital of ScrantonCompletedCardiovascular Diseases | Bleeding | Catheter Complications | Occlusion of Artery | Arterial PunctureUnited States, India